OncoTherapy Science, Inc. (4564.T)
JPY 23.0
(-4.17%)
JPY 23.0
(-4.17%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 943.08 Million JPY | -17.86% |
| 2022 | 1.14 Billion JPY | -47.01% |
| 2021 | 2.16 Billion JPY | 30.71% |
| 2020 | 1.65 Billion JPY | -22.53% |
| 2019 | 2.13 Billion JPY | -33.85% |
| 2018 | 3.23 Billion JPY | 1.08% |
| 2017 | 3.19 Billion JPY | -2.77% |
| 2016 | 3.29 Billion JPY | 1.33% |
| 2015 | 3.24 Billion JPY | 18.86% |
| 2014 | 2.73 Billion JPY | -43.12% |
| 2013 | 4.8 Billion JPY | 9.39% |
| 2012 | 4.39 Billion JPY | -12.87% |
| 2011 | 5.03 Billion JPY | -1.91% |
| 2010 | 5.13 Billion JPY | 4.03% |
| 2009 | 4.93 Billion JPY | 49.65% |
| 2008 | 3.3 Billion JPY | 39.95% |
| 2007 | 2.35 Billion JPY | 9.52% |
| 2006 | 2.15 Billion JPY | 7.76% |
| 2005 | 1.99 Billion JPY | 29.34% |
| 2004 | 1.54 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 109 Million JPY | -0.15% |
| 2023 Q3 | 227.55 Million JPY | -13.1% |
| 2023 Q2 | 261.87 Million JPY | -23.98% |
| 2023 Q1 | 344.48 Million JPY | 33.04% |
| 2023 Q4 | 109.16 Million JPY | -52.03% |
| 2023 FY | 943.08 Million JPY | -17.86% |
| 2022 Q3 | 267.81 Million JPY | 0.1% |
| 2022 Q4 | 258.93 Million JPY | -3.32% |
| 2022 FY | 1.14 Billion JPY | -47.01% |
| 2022 Q2 | 267.55 Million JPY | -24.38% |
| 2022 Q1 | 353.79 Million JPY | -22.59% |
| 2021 Q4 | 457.06 Million JPY | -38.15% |
| 2021 Q3 | 739.01 Million JPY | 93.23% |
| 2021 FY | 2.16 Billion JPY | 30.71% |
| 2021 Q2 | 382.46 Million JPY | -34.96% |
| 2021 Q1 | 588.01 Million JPY | 26.17% |
| 2020 Q3 | 404.28 Million JPY | -4.01% |
| 2020 FY | 1.65 Billion JPY | -22.53% |
| 2020 Q4 | 466.04 Million JPY | 15.28% |
| 2020 Q1 | 365.96 Million JPY | -29.63% |
| 2020 Q2 | 421.18 Million JPY | 15.09% |
| 2019 Q2 | 563.22 Million JPY | -1.12% |
| 2019 Q3 | 486.71 Million JPY | -13.58% |
| 2019 Q1 | 569.57 Million JPY | -32.23% |
| 2019 FY | 2.13 Billion JPY | -33.85% |
| 2019 Q4 | 520.03 Million JPY | 6.84% |
| 2018 Q2 | 1.02 Billion JPY | 40.98% |
| 2018 FY | 3.23 Billion JPY | 1.08% |
| 2018 Q4 | 840.46 Million JPY | 30.59% |
| 2018 Q1 | 726.32 Million JPY | -6.81% |
| 2018 Q3 | 643.57 Million JPY | -37.15% |
| 2017 Q1 | 794.08 Million JPY | -7.74% |
| 2017 FY | 3.19 Billion JPY | -2.77% |
| 2017 Q4 | 779.36 Million JPY | -1.77% |
| 2017 Q3 | 793.44 Million JPY | -4.74% |
| 2017 Q2 | 832.95 Million JPY | 4.89% |
| 2016 FY | 3.29 Billion JPY | 1.33% |
| 2016 Q2 | 770.41 Million JPY | -1.71% |
| 2016 Q4 | 860.66 Million JPY | -1.75% |
| 2016 Q3 | 875.97 Million JPY | 13.7% |
| 2016 Q1 | 783.82 Million JPY | 2.18% |
| 2015 Q4 | 767.06 Million JPY | -3.95% |
| 2015 FY | 3.24 Billion JPY | 18.86% |
| 2015 Q1 | 878.49 Million JPY | 20.55% |
| 2015 Q2 | 803.65 Million JPY | -8.52% |
| 2015 Q3 | 798.58 Million JPY | -0.63% |
| 2014 Q1 | 638.49 Million JPY | -38.69% |
| 2014 FY | 2.73 Billion JPY | -43.12% |
| 2014 Q2 | 793.87 Million JPY | 24.34% |
| 2014 Q3 | 571.34 Million JPY | -28.03% |
| 2014 Q4 | 728.71 Million JPY | 27.54% |
| 2013 Q1 | 1.27 Billion JPY | 19.61% |
| 2013 Q3 | 1.34 Billion JPY | 17.58% |
| 2013 FY | 4.8 Billion JPY | 9.39% |
| 2013 Q4 | 1.04 Billion JPY | -22.48% |
| 2013 Q2 | 1.14 Billion JPY | -10.45% |
| 2012 Q2 | 1.16 Billion JPY | 5.95% |
| 2012 Q1 | 1.09 Billion JPY | -23.65% |
| 2012 FY | 4.39 Billion JPY | -12.87% |
| 2012 Q3 | 1.06 Billion JPY | -8.06% |
| 2012 Q4 | 1.06 Billion JPY | -0.07% |
| 2011 Q4 | 1.43 Billion JPY | 30.05% |
| 2011 Q1 | 1.35 Billion JPY | -0.59% |
| 2011 Q2 | 1.14 Billion JPY | -15.65% |
| 2011 Q3 | 1.1 Billion JPY | -3.56% |
| 2011 FY | 5.03 Billion JPY | -1.91% |
| 2010 Q1 | 1.07 Billion JPY | -11.47% |
| 2010 Q2 | 1.26 Billion JPY | 18.11% |
| 2010 Q3 | 1.43 Billion JPY | 13.14% |
| 2010 Q4 | 1.36 Billion JPY | -4.81% |
| 2010 FY | 5.13 Billion JPY | 4.03% |
| 2009 Q1 | 1.06 Billion JPY | 6.38% |
| 2009 FY | 4.93 Billion JPY | 49.65% |
| 2009 Q4 | 1.21 Billion JPY | -10.47% |
| 2009 Q3 | 1.35 Billion JPY | 3.36% |
| 2009 Q2 | 1.3 Billion JPY | 23.07% |
| 2008 FY | 3.3 Billion JPY | 39.95% |
| 2008 Q3 | 789.65 Million JPY | 0.0% |
| 2008 Q4 | 1 Billion JPY | 26.67% |
| 2007 FY | 2.35 Billion JPY | 9.52% |
| 2006 FY | 2.15 Billion JPY | 7.76% |
| 2005 FY | 1.99 Billion JPY | 29.34% |
| 2004 FY | 1.54 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 26.578% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -63.498% |
| GNI Group Ltd. | 9.32 Billion JPY | 89.884% |
| Linical Co., Ltd. | 2.7 Billion JPY | 65.138% |
| Trans Genic Inc. | 2.15 Billion JPY | 56.335% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 36.755% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 69.291% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 49.214% |
| AnGes, Inc. | 8.9 Billion JPY | 89.406% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 95.086% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -128.354% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 3.311% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 63.27% |
| CanBas Co., Ltd. | 278 Million JPY | -239.238% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 17.385% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 48.124% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 41.196% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 60.276% |
| PeptiDream Inc. | 9.68 Billion JPY | 90.265% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 51.898% |
| Ribomic Inc. | 1.1 Billion JPY | 14.707% |
| SanBio Company Limited | 4.53 Billion JPY | 79.223% |
| Healios K.K. | 3.48 Billion JPY | 72.954% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 18.329% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 29.329% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 32.803% |
| StemRIM | 2.07 Billion JPY | 54.572% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 51.969% |
| FunPep Company Limited | 313.82 Million JPY | -200.516% |
| Kringle Pharma, Inc. | 958.01 Million JPY | 1.559% |
| Stella Pharma Corporation | 963.98 Million JPY | 2.168% |
| TMS Co., Ltd. | 943.25 Million JPY | 0.018% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 13.475% |
| Cuorips Inc. | 598.11 Million JPY | -57.675% |
| K Pharma,Inc. | 543.94 Million JPY | -73.379% |
| Takara Bio Inc. | 23.9 Billion JPY | 96.055% |
| ReproCELL Incorporated | 1.51 Billion JPY | 37.71% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 20.347% |
| StemCell Institute Inc. | 1.16 Billion JPY | 18.848% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 38.048% |
| CellSeed Inc. | 804.93 Million JPY | -17.163% |